Farmas USA

Estoy con el movil y no puedo investigar, pero lo de que le han quitado la cita con la FDA a ACHN no tiene que ver con que le han dado ya Fast Track?

ya empiean los rumores de Buyout en ACHN tb en foros usanos...jaja

mira que les gusta!!

los paquetes gordos de antes han sido estos

10:36:22 $ 6.78 10,000
10:00:26 $ 6.70 28,200
10:06:03 $ 6.75 12,684
10:23:12 $ 6.75 10,000
09:57:04 $ 6.65 16,100
09:56:25 $ 6.67 24,300

paquetitos buenos que van pillando,eh!!! me gusta!!

efectivamente supongo que es asi...

Ya sabemos que la fecha que da la FDA es fecha maxima,pero a veces se adelantan, y mucho

he encontrado este enlace, es del 15 de MAyo,es noticia similar
http://www.stockstobuy.org/forum/topics/achillion-pharmaceuticals-achn-receives-fda-fast-track-status-on-

y aqui sale del 17 de agosto la referencia de la FDA con la noticia de ACHN
http://www.theflyonthewall.com/permalinks/entry.php?symbol=GILD;VRTX;ACHN;IDIX

se nos paso esto creo el otro dia, no me acuerdo de verlo publicado por aqui, es del 16 de Agosto

JMP Securities upgraded shares of Achillion Pharmaceuticals Inc (ACHN) from a market perform rating to an outperform rating. JMP Securities now has a $10.00 price target on the stock.

fuente: http://www.marketwatch.com/story/equity-briefing-upgrades-and-downgrades-for-august-16th-abc-abfs-achn-ale-amat-anf-avnw-axp-beav-2012-08-16

Mas sobre ACHN, como me habeis dejado solo, yo voy poniendo hoy que puedo..jaja

Explica la diferencia entre las NUCS y el PI, que yo no lo sabia

A sector I am watching today is the hepatitis C companies with candidate treatments in the pipelines. There are two main kinds of treatments, the nucleotides ("nucs") and the Protease Inhibitors (PI).

IDIX has the nuc and ACHN has the PI. Both have been promising in trials although the focus has been somewhat more on the nuc co's over the PIs since GILD bought VRUS for their nuc and paid way up, near $11 Billion for the company.

This morning we see that IDIX's candidate got a clinical hold by the FDA for a cardiac related adverse affect in a competitor's Nuc drug.

With ACHN now floating about in the 6's and IDIX stock tanking , this area is an interesting one to watch. The thing about a clinical hold is that it can last many weeks and months before the FDA due process is completed and they make a decesion. By then, much of the trial data that was held up can be compromised causing a serious delay.

These events seem to give ACHN a new advantage in the sector making it a noteworthy area to watch. I'll leave it at that for now.

Sii!! Es lo lei el otro dia que la FDA esta dando buenos palos a los que van por la senda de los nucleotidos debido a problemas cardiacos. De ahi lo del 'hold' de IDIX.
Y cuantos menos competidores queden en esto ... Mas mercado todito él para ACHN ... Buy out a la vista, claro

Raclit, a ver si ves mi paquete recien ordenado.
Te doy una pista , EL NUMERO DE LA BESTIA
ACHN